Clinical stage T3 prostate cancer. Natural history, treatment options and results;Cancer de prostate de stade T3 clinique: Histoire naturelle, les choix thérapeutiques et leurs résultats

Progres en Urologie

Volumn 8, Issue 6, 1998, Pages 977-993

  Peneau, Michel ^a   Piéchaud, Thierry ^b   Cariou, Gérard ^c   Ragni, Evelyne ^d   Fontaine, Eric ^e   Fournier, Georges ^f  

^a CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^b CLINIQUE SAINT AUGUSTIN   (France)

^c Hopital des Diaconesses   (France)

^d HÔPITAL NORD   (France)

^e HÔPITAL AMBROISE PARÉ   (France)

^f SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Adjuvant therapy; Endocrine therapy; Neoadjuvant therapy; Prostate cancer; Radical prostatectomy; Radiotherapy; Stage T3; Surgery

Indexed keywords

HORMONE;

ADJUVANT CHEMOTHERAPY; ADULT; AGE; AGED; BRACHYTHERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE; PROSTATE TUMOR; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TIME;

ADULT; AGE FACTORS; AGED; BRACHYTHERAPY; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HORMONES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MULTICENTER STUDIES; PALLIATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS;

EID: 0032253256     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (148)

1. ADOLFSSON J. Deterred treatment of low grade slage T3 prostate cancer without distant metastases. J. Urol., 1993 149, 326-329.
2. ALLAIN Y.M., BOLLA M., BRUNE D., CASTELAIN B., CELLIER P., CUILLERE J.C., DOUCHEZ J., GESLIN J , HAY M., HEINTZ J. Prostate cancer : results of radiotherapy in French institutes. J.Eur Radioth ,1987, 8 177-187.
3. ANDROS E .A., DANESHGARI F., CRAWFORD ED : Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate. Clin Invest Med., 1993, 16 : 510-515.
4. ANSCHER M.S., PROSNITZ L R. : Post-operative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicles involvement and/or penetration through the capsule. J. Urol., 1987, 138 . 1407-1412.
5. ANSCHER M.S., ROBERTSON C.N., PROSNITZ L.R. : Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate. Int. J. Radiat. Oncol. Biol Phys 1995, 33 : 37-43.
6. APRIKIAN A.G. FAIR W.R., REUTERV.E, SOGANI P., HERR H., RUSSO P., SHEINFELD J : Experience with neoadjuvant diethystilboestrol and radical prostatectomy in patients with locally advanced prostate cancer. Br J. Urol, 1994, 74 : 630-636.
7. ARO J., HAAPIAINEN R., KAJANTI M., RANNIKKO S., ALFTHAN O., and the Finnprostate Group. Comparison of endocrine and radiation therapy in locally advanced prostatic cancer. Eur. Urol, 1988, 15 : 182-186.
8. BAGSHAW, M.A., Potential for radiotherapy alone in prostatic cancer. Cancer, 1985, 55 : 2079-2085
9. BAGSHAW. M.A , KAPLAN I.D, COX R.C. : Radiation therapy for localized disease. Cancer, 1993, 71 . 939-952.
10. BERNER A. HARVEI S., TRELI S., FOSSA S.D., NESLAND J.M. : Prostatic carcinoma. a multivariate analysis of prognostic factors. Br. J. Cancer, 1994, 69 : 924-930.
11. BOLLA M. Personal Communication, First International consultation on prostate cancer, Monaco, 1996.
12. BOSCH R.J., KURTH K.H., SCHROEDER FH., Surgical treatment of locally advanced (T3) prostatic carcinoma : early results. J. Urol, 1987, 138 : 811-821.
13. BRINDLE J.S., MARTINEZ A., SCHRAY M., EDMUNDSON G., BENSON R.C., ZINCKE H., DIOKNA A., GONZALEZ J. Pelvic lymphadenectomy and transperineal implantation of IR.192 combined with external beam radiotherapy for bulky stage C prostatic carcinoma. Int. J.Radiat. oncol. Biol. Phys., 1989, 17 : 1063-1066.
14. BYAR D. P. : The veterans administration cooperative urological research group's studies of cancer of the prostate. Cancer, 1973, 1126-1130.
15. BYAR D.P. : The VACURG's studies of cancer of the prostate. Cancer, 1977, 32 : 1126-1130.
16. BYAR D.P., CORLE D.K. : Hormone therapy for prostate cancer : Results of the Veterans Administration Cooperative Urological Research Group Studies. NCI Monogr., 1988, 7 : 165-170.
17. CAMA C., OLSSON C.A., RAFFO A.J., PERLMAN H., BUTTYAN R., O'TOOLE K., Mc MAHON D., BENSON M.C., KATZ A.E. Molecular staging of prostate cancer II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen. J. Urol., 1995, 153: 1373-1378
18. CARROLL P.R., Prostate cancer. Efficient use of imaging and new treatment techniques. Prostate cancer treatment stage by stage : Personnal Communication, Evening Seminars, AUA. 1996.
19. CATALONA W.J. STEIN A.J. : Staging errors in clinically localized prostatic cancer. J. Urol., 1982, 127 : 452-456.
20. CATALONA W.J., MILLER D.R., KAVOUSSI L.R. Intermediate term survival results in clinically understaged prostate cancer patients following radical prostatectomy, J Urol., 1988, 140: 540-543.
21. CATALONA W.J., SCOTT W W : Carcinoma of the prostate : In Campbell's urology, (Eds) Walsh P.C., Gittes R.F., Perlmutter A.D. et al. Fifth edition. Chapter 32 : 1463-1534. Philadelphia, 1986, Saunders.
22. CHENG, W.S. FRYDENBERG M , BERGSTRALH, E.I., LARSON-KELLER J.J., ZINCKE H. Radical prostatectomy for pathologic stage C prostate cancer . Influence of pathologic variables and adjuvant treatment on disease outcome. Urology , 1993, 42 . 283-29.
23. CHER M.L., SHINOHARA K., BRESLIN S. VOPNEK J., CARROLL P.R., High failure rate associated with long term follow up of neoadjuvant androgen deprivation folowed by radical prostatectomy for stage C prostatic cancer : Br. J. Urol. 1995, 75 : 771-777.
24. CORNUD F., BELIN X., FLAM T., CHRETIEN Y., DESLIGNIERES S., PARAF F., CASANOVA J.M., THIOUNN N., HELENON O., DEBRE B., DUFOUR B., MOREAU J.F. Local staging of prostate cancer by endorectal MRI using fast spin echo sequence: prospective correlation with pathological findings after radical prostatectomy. Brit. J. Urol., 1996, 77: 843-850.
25. CROOK J., ROBERTSON S., COLLI. G., ZALESKI V., ESCHE B. Clinical relevance of transrectal ultrasound biopsy and serum prostate specific antigen following external beam radiotherapy for cacinoma of the prostate. Int J. Radiot. Oncol. Biol. Phys., 1993, 27 : 31-37.
26. CUSSENOT O., RAVERY V., DESGRADCHAMPS F., COCHAND-PRIOLLET B., TEILLAC P., LE DUC A.: Facteurs pronostiques du cancer de la prostate. Revue de la littérature et perspectives d'avenir. Prog. Urol., 4: 17-30. 1994.
27. DEBRUYNE F., FOSTER G., SCHULMANN C.C., VAN CANGH P.J., WITJES W.P.J. European study of neoadjuvant combined androgen deprivation therapy in T2-3, NO, MO prostatic carcinoma. J. Urol. 1996, 155 : (P) 645A.
28. DE REDDER D., ELGAMAL. A.A., WERBROUCK P., ACKAERT K., VAN POPPEL H., Hormone-therapy before radical prostatectomy. Effects on surgical method and resection margins (Belg. Uro-oncol. Study group). Acta. Urol. Belg. 1994, 62 : 61-65.
29. DE VRIES G.M., OLSSON C.A., BENSON M.C., CONNOR J.P., BUTTYAN R., KATZ A.E. Qualitative and quantitative RT-PCR PSA : Molecular staging of prostate cancer. J. Urol., 1996, 155 : 417 A (abst. 426).
30. DOUCHEZ J., ALLAIN Y.M., CELLIER P., FENTON J., FREGEVU Y., HAY M., LE BOURGEOIS J.P., VINCENT F. Cancer de la prostate : intolerance et morbidité de la radiotherapie externe. Bull. Cancer (Paris), 1985, 72 : 573-577.
31. DUMAS F., ESCHWEGE P., BLANCHET P., BENOIT G., JARDIN A., LACOUR B., LORIC S. Molecular staging of clinically localized Prostate Cancer using PSA and PSMA RT-PCR Assays : Lack of predictive value. J. Urol., 1997, 157 (suppl.) : 110 (abst. 429)
32. DUNCAN W , WARDE P., CATTON C.N., MUNRO A.J., LAKIER R., GADALLA T., GOSPODAROWICZ M.K. : Carcinoma of the prostate : results of radical radiotherapy (1970-1985). Int. J. radiat. Oncol. Biol. Phys., 1993, 26 : 203-210.
33. DUPONT A., CUSAN L., GOMEZ J.L., KOUTSILIERIS M., SUBURU R., EDMOND J., LABRIE F. Combination Therapy with Flutamide and the LHRH Agonist D - Trp 6, des-Gly - NH 2 10 ] LHRH Ethylamide in Stage C Prostatic Carcinoma. Br. J. Urol. (Pans) 1993, 72, 629-634.
34. EBERT T., SCHMITZ-DRAGER B., BURRIG K., MILLER S., PAULI N., KAHN T., ACKERMANN R. : Accuracy of Imaging modalities in staging the local extent of prostate cancer. Urol. Clin. North. Am., 1991, 18 : 453-457
35. ELLIS W.J., COREY, E., MELCHIOR S., ARFMAN E., OSWIN M., VESSELLA R., LANGE P.H. Dectection of PSA producing cells in the circulation through RT-PCR in men with prostate cancer. J. Urol., 1997, 157 (suppl.) : 110 (abst. 427).
36. ENNIS R.D., PESCHEL R.E. Radiation therapy for prostate cancer. Long term results and implications for future advances. Cancer, 1993, 72 : 2644-2650.
37. FALLON B. WILLIAMS R.D. : Current options in the management of clinical stage C prostatic carcinoma Urol. Clin. North. Am., 1990, 17 : 853-866.
38. FELLOWS G.J., CLARK P.B., BEYNON L.L., BOREHAM J., KEEN C., PARKINSON M.C., PETO R., and WEBB J.N , : Treatment of Advanced Localised Prostatic Cancer, Orchiectomy, Radiotherapy, or Combined Treatment. A Medical Research Council Study. . Br. J. Urol. 1992, 70, 304-309.
39. FOURNIER G., MANGIN P. : Traitement du cancer de prostate métastasé. Press. Med., 1995, 32 : 1465-1470.
40. FREIHA F.S., BAGSHAW, M.A. Carcinoma of the prostate. Results of post-irradiation biopsy. The Prostate, 1984, 5 : 19-24.
41. GEORGE N.J.R. : Natural history of localized prostatic cancer. Lancet, 1988, 1: 494-497
42. GERBER G.S., THISTED R.A., CHODAK G.W., RUKSTALIS D.B., PAULSON D.F., MIDDELTON A.W., OHORI M., SCARDINO P.T., FROHMULLER H.G.W., SCHROEDER F.H., SMITH J.A., SCHELLHAMMER P.F. Results of radical prostatectomy in men with locally advanced (clinical stage T3) prostate cancer : multiinstitutional analysis. J. Urol., 1996, 155 (suppl) : (P) 609 A.
43. GERVASI L.A., MATA J., EASLEY J.D., WILBANKS J.H., SEALE-HAWKINS C., CARLTON C.E. Jr, SCARDINO P.T. : Prognostic significance of lymph nodal metastases in prostate cancer. J. Urol., 1989, 142 : 332-336.
44. GIBBONS R.P., COLE B.S , RICHARDSON R.G., CORREA R.J. Jr., BRANNEN G.E., MASON J.T., TAYLOR W.J., HAFERMANN M.D. Adjuvant radiotherapy following radical prostatectomy : results and complications. J. Urol., 1986, 135 : 65-68.
45. GOMELLA L.G., LIBERMAN S.N., MULHOLLAND S.G., PETERSEN R.O., HYSLOP T., CORN, B.W. Induction androgen deprivation plus prostatectomy for stage T3 disease : failure to achieve prostate specific antigen based freedom from disease status in a phase II trial. Urology, 1996, 47 : 870-877.
46. GRESKOVICH F.J., JOHNSON D.E., TENNEY D.M., STEPHENSON R.A. : Prostate specific antigen in patients with clinical stage C prostate cancer : Relation to lymph node status and grade J. Urol , 1991, 145 : 798-801.
47. GRUPS J.W., THEISS M. FROHMÜLLER H.G.W. Complications of radical prostatectomy : Stage B versus stage C Carcinoma of the prostate. Eur. Urol., 1990, 18 : 37.
48. GUITER J.: Histoire naturelle du cancer de la prostate. J. Urol., 1987, 8 469-474.
49. HALL R.R., BEYNON L.L., HORWICH A., KAYES S., TOLLEY D. Urology and the TNM classification, Lancet, 1988, 1145-1146.
50. HANCOCK S.L , COX R.S., BAGSHAW M.A. Prostate-specific antigen after radiotherapy for prostate cancer : a revaluation of long term biochemical control and the kinetics of recurrence in patients treated at Stanford university. J. Urol., 1995, 154 : 1414-1417.
51. HANKS G.E., DIAMOND J.J., KRALL J.M., MARTZ K.L., KRAMER S. A ten year follow up of 682 patients treated for prostate cancer with radiation therapy in the United States Int. J. Radiat. Oncol. Biol. Phys., 1987, 13 : 499-505.
52. HOLZMAN M., CARLTON C.E., SCARDINO P.T. : The frequency and morbidity of local tumor recurrence after definitive radiotherapy for stage C prostate cancer. J. Urol, 1991, 146 : 1578-1582.
53. ISRAELI R.S., POWELL C.T., FAIR W.R., HESTON W.D. : Molecular cloning of a complementary DNA encoding a prostate specific membrane antigen. Cancer Res., 1993, 53: 227.
54. JACOBSON G.M , SMITH, J.A., STEWART, J.R. Post-operative radiation therapy for pathologic stage C prostate cancer. Int J. Radiat Oncol. Biol. Phys., 1987, 13 : 1021-1024.
55. JOHANSSON J.E., ADAMI H.O., ANDERSSON S.O., BERGSTROM R., KRUSEMO U.B., KRAAZ W. Natural history of localized prostate cancer: a population based study in 223 untreated patients. Lancet, 1989, 1 : 799-803.
56. KABALIN J.N., HODGE K.K., MCNEAL J.E., FREIHA F.S., STAMEY T.A. Identification of residual cancer in the prostate following radiation therapy : role of transrectal ultrasound. J. Urol., 1989, 142 : 326-331.
57. KAPLAN I.D., COX R.S., BAGSHAW M.A. Prostate specific antigen after external beam radiotherapy for prostatic cancer- follow up. J. Urol., 1993, 149 : 519-522.
58. KAPLAN I.D., PRESTIDGE D.R., BAHSHAW M.A., COX R.S. The importance of local control in the treatment of prostate cancer. J. Urol., 1992, 147 : 917-921.
59. KATZ A.E., OLSSON C A., RAFFO A.J., CAMA C., PERLMAN H., SEAMAN E., O'TOOLE K.M., Mc MAHON D., BENSON M.C., BUTTYAN R., Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase - PCR assay. Urology, 1994, 43: 765-775.
60. KATZ A.E., DE VRIES G.H., BEGG M.D., RAFFO A.J., CAMA C., O'TOOLE K.M., BUTTYAN R., BENSON M.C., OLSSON C.A. Enhanced reverse transcriptase polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer Cancer, 1995, 75 : 1642-1648.
61. KAVADI V.S., ZAGARS G.K., POLLACK A. : Serum prostate specific antigen after radiation therapy for clinically localized prostate cancer : prognostic implications. Int. J.Radiat. oncol. Biol. Phys., 1994, 30 : 279-287.
62. KAYE K.W., OLSON D.J., PAYNE J.T. Detailed preliminary analysies of 125-Iodine implantation for localized prostate cancer using percutaneous approach. J Urol., 1995, 153 : 1020-1025.
63. KLEER E., OESTERLING J.E. : PSA and staging of localized prostate cancer Urol. Clin. North. Am., 1993, 20 : 695-704.
64. KLOTZ L.H., GOLDENBERG L.S., BULLOCK M.J., SRIGLEY J.R., LAPALANTE S. Neoadjuvant cyproterone acetate ( C.P.A.) therapy prior to radical prostatectomy reduces tumor burden and margin positivity without altering 6 and 12 month post-treatment PSA : results of a randomized trial. J. Urol., 1996.155 (suppl.) : (P) 399 A.
65. KOPROWSKI C.D., BERKENSTOCK K.G., BOROFSKI A.M., ZIEGLER J.C , LIGHTFOOT D.A , BRADY L.W. External beam radiation versus 125 Iodine Implants in the definitive treatment of prostate carcinoma. Int. J.Radiat. Oncol. Biol. Phys., 1991, 21 : 951-960.
66. KUBAN D.A., EL-MAHDI A.M., SCHELLHAMMER P.F. : Iodine 125 interstitial implantation for prostate cancer: what have we learned 10 years later? Cancer, 1989, 63 2415-2420.
67. KUBAN D.A., EL-MAHDI A.M., SCHELLHAMMER P.F. The significance of post-irradiation prostate biopsy with long term follow up Int J. Radiat. Oncol. Biol. Phys., 1992, 24 . 409-414.
68. KUBAN D.A., EL-MAHDI A.M , SCHELLHAMMER P.F., Prostate specific antigen for pretreatment prediction and post-treatment evaluation of outcome after definitive irradiation for prostate cancer. Int. J. Radiat. Oncol Biol. Phy., 1995, 32 : 307-316.
69. KURTH K H., ALTWEIN J.E., SKOLUDA D, HOHENFELLNER, R. Follow up of irradiated prostatic carcinoma by aspiration biopsy. J. Urol., 1977, 117 : 615-617.
70. LAI P.P., PILEPICH M.V., KRALL J M., ASBELL S.O., HANKS G.E., PERE, C.A., RUBIN P., SAUSE W.T , COX J D. The effect of overall treatment time on the outcome of definitive radiotherapy for localized prostate carcinoma : the radiation therapy oncology group 7506 and 7706. experience. Int. J. Radiat. Oncol. Biol. Phys., 1991, 21 : 925-933.
71. LAVERDIERE J., GOMEZ J.L., CUSAN L., SUBURU E.R , DIAMOND P., LEMAY M., CANDAS B., LABRIE F. Beneficial effect of combination therapy administerad prior and following external beam radiation therapy in localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1995, 32 : (P) 189.
72. LAWTON C.A., WON M., PILEPICH M.V., ASBELL S.O , SHIPLEY W.U., HANKS G.E., COX J.D., PEREZ C.A., SAUSE W.T., DOGGETT S.R.L., RUBIN P. Long term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate : analysis of RTOG studies 7506 and 7706 Int J. Radiat. Oncol. Biol. Phys, 1991, 21 : 935-939.
73. LERNER S.E., BLUTE M.L., ZINCKE H. Extended experience with radical prostatectomy for clinical stage T3 Prostate cancer. Outcome and contemporary morbidity. J. Urol., 1995, 154 : 1447-1452
74. LIEBER M.M. . Practical clinical utility of DNA ploidy for managing patients with prostate carcinoma. Urology, 1995, 45 : 558-559.
75. LIM A.J , BRANDON, A.H., FIEDLER, J., BRICKMAN, A.L., BOYER, C.I., RAUB, W.A., SOLOWAY, M.S. Quality of life : radical prostatectomy versus radiation therapy for prostate cancer. J. Urol., 1995, 154 : 1420-1425.
76. LINK P., FREIHA H.S., STAMEY T.A. Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy J. Urol., 1991, 145 : 532-534.
77. LYNCH J.H., GRAHA, C.W. Management of stage C adenocarcinoma of the prostate. Br. J. Urol., 1992, 70 : 50-56.
78. MAEDA O., MEGURO N., SAIKI S., KINOUCHI T., KUROBA M., USAMI M., KOTADCE T., Preoperative endocrine therapy in patients with locally advanced prostate cancer. Jap. J. Clin. Oncol., 1995, 25 : 135-139
79. MARTINEZ A. : Experience with LDR and conformal HDR Brachytherapy for locally advanced prostate cancer. Personnal communication; Prostate cancer, the role of interstitial implantation : Fourth Annual Symposium. Seattle, June 1993.
80. Mc CAMMON K.A., and SCHELLHAMMER P.F. Comparison of quality of life after radiation therapy or radical retropublic prostatectomy for localized carcinoma of the prostate. J. Urol., 1996, 155 (suppl) : (abst. 1344).
81. Mc CARTHY J.F., CATALONA W.J., HUDSON M.A. Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy : early versus delayed treatment. J. Urol., 1994, 151 . 1575-1578.
82. Mc CARTHY J.F., HUDSON M.A., CATALONA W.J Radiation therapy after radical prostatectomy : long-term followup. J.Urol , 1996. 155 (suppl.), (P) 608 A.
83. MEIER R., MARK R., St ROYAL L., TRAN L., COLBURN G , PARKER R. Postoperative radiation therapy after radical prostatectomy for prostate carcinoma. Cancer. 1992, 70 : 1960-1966.
84. METTLIN C., JONES G.W., MURPHY G.P. Trends in prostate cancer care in the United States, 1974-1990 : observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA Cancer J. Clin., 1993, 43 . 83-9.
85. MORGAN, W R , BERGSTRALH, E J., ZINCKE, H. Long term evaluation of radical prostatectomy as treatment for clinical stage C (T3) Prostate cancer. Urology, 1993, 41 : 113-120.
86. MOSKOVITZ B , NITECKI S., LEVIN D.R : Cancer of the prostate is there a need for aggressive treatment ? Urol Int, 1987, 42: 49-52.
87. MOTTRI, A.M., MAPPES C , STÖCKLE M., MÜLLER S.C., VOGES G.E. Neoadjuvant hormonal treatment in clinical stage C prostate cancer J. Urol , 1993, 149 (suppl) : (P) 347 A.
88. NARAYAN P., GAJENDRAN V., TAYLOR S.P., TEWARI A., PRESTI J.C. Jr, LEIDICH R., LO R., PALMER K., SHINOHARA K., SPAULDING J.T. . The role of transrectal ultrasound guided biopsy-based staging, preoperative serum Prostae specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology, 1995, 46 . 205-212.
89. NARAYAN P., LOWE B.A., THOMPSON I.M., CARROLL P.R. Neoadjuvant hormonal therapy and radical prostatectomy for clinical stage C carcinoma of the prostate. Br. J. Urol., 1994, 73 : 544-548.
90. OHORI M , GOAD J.R., WHEELER T.M., EASTHAM J.A., THOMPSON T.C., SCARDINO P.T. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J. Urol , 1994, 152 : 1843-1849.
91. OHORI M., WHEELER T.M., KATTAN M.W., GOTO Y., SCARDINO P.T. Pronostic significance of positive surgical margins in radical prostatectomy specimens. J. Urol., 1995, 154 : 1818-1824.
92. OKEGAWA T., YOSHIOKA J., MORITA R., NUTAHARA L.C., TSUKADA Y., HIGASHIHARA E. Comparison of the nested reverse transcriptase polymerase chain reaction (P.C.R.) assay for prostate specific antigen (P.S.A.) versus prostate specific membran antigen (P.S.M.A.) in the molecular staging of prostatic cancer. J. Urol., 1997, 157 (suppl.) : (P) 120 A
93. OLSSON C.A., DE VRIES G.M., BENSON M.C., RAFFO A., BUTTYAN R , CAMA C., O'TOOLE K., KATZ A.E. The use of RT-PCR for prostatic specific antigen assay to predict potential surgical failures before radical prostatectomy : Molecular staging of prostate cancer. Br. J. Urol., 1996, 77 : 411-417.
94. OLSSON C.A., DE VRIES G.M., BUTTYAN R., KATZ A.E. Reverse transcriptase polymerase chain reaction assay for prostate cancer. Urol. Clin. North Am, 1997, 24 : 367-378.
95. OUTWATER E.K., PETERSEN R.O., SIEGELMAN E.S., GOMELLA L.G., CHERNESKY C.E., MITCHELL D.G. : Prostate carcinoma: assessment of diagnostic criteria for capsular penetration on endorectal coil MR images. Radiology, 1994, 193: 333-339.
96. PANDEY P., FOWLER J.E., SEAVER L.E., FELIZ T.P., BROOKS J.P. : Ultrasound guided seminal vesicle biopsies in men with suspected prostate cancer. J. Urol., 1995, 154 . 1798-1801.
97. PAULSON D.E. HODGE G. B. JR, HINSHAW W. And the Uro-Oncology Research Group. : Radiation therapy versus delayed androgen deprivation for stage C carcinoma of the prostate. J. Urol., 1984, 131, 901-903.
98. PAVONE-MACALUSO M., DE VOOGT H.J., VIGGIANO G., BARASOLO E., LARDENNOIS B , DE PAUW M., and SYLVESTER R. : Comparison of diethylstilbestrol, cyprogerone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer . final analysis of a randomized phase III trial of the european organization for research on treament of cancer urological group. : J. Urol., 1986, 136 : 624-631.
99. PEREZ, C A., GARCIA, D , SIMPSON, J.R., ZIVNUSKA, F., LOCKETT, M.A Factors influencing outcome of definitive radiotherapy for localized carcinoma of the prostate. Radiother. Oncol., 1989, 16 . 1-21.
100. PEREZ, C.A., PILEPICH, M.V., ZIVNUSKAJ, F. Tumor control in definitive irradiation for localized carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phy. 1986, 12 : 523-531.
101. PILEPICH M V., CAPLAN R., BYHARDT R.W., LAWSON C A., GALLAGHER M.J., MESIC J.B., HANKS G E., COUGHLIN C.T., PORTER A. Phase III trial of adjuvant androgen suppression using goserelin in patients with carcinoma of the prostate treated with definitive radiotherapy (results of RTOG 85-31). Int. J. Radiat Oncol. Biol. Phys., 1995, 32 (suppl) : (P) 188.
102. PILEPICH M.V., KRALL J.M, AL SARRAF M. A phase III trial of androgen suppression before and during radiation therapy for locally advanced prostatic carcinoma . preliminary report of RTOG protocol 86-10 Proc. Am. Soc. Clin. Oncol., 1993, 12 : 229.
103. PILEPICH M.V., KRALL J.M., AL SARRAF M., JOHN M.J., DOGGETT R L., SAUSE W.T., LAWTON C.A , ABRAMS R.A , ROTMAN M., RUBIN P. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma : a randomized comparative trial of the radiation therapy oncology group. Urology, 1995, 45 : 616-623.
104. PILEPICH M.V., PEREZ C.A., WALZ B.J., ZIVNUSKA F.R. Complications of definitive radiotherapy for carcinoma of the prostate. Int. J. Radiat. Oncol Biol. Phys., 1981, 7 : 1241-1348.
105. POLLACK A., ZAGENS G.K., KOPPLIN S. . Radiotherapy and androgen ablation for clincally localized nigh risk prostate cancer : Int J. Radiat. Oncol. Biol. Phys., 1995, 32 : 13-20.
106. PRESTIDGE D.R., KAPLAN I., COX R.S., BAGSHAW M.A. Predictors of survival after a positive post-irradiation prostate biopsy. Int. J. Radiat. Oncol. Biol. Phys., 1994, 28 : 17-22.
107. PRESTIDGE D.R., KAPLAN I., COX, R.S , BAGSHAW M.A. The clinical significance of a positive post irradiation prostatic biopsy without metastases. Int. J. Radiat. Oncol. Biol. Phys., 1992, 24 : 403-408.
108. QUINN S.F., FRANZINI D.A., DEMLOW T.A., ROSENCRANTZ D.R., KIM J., HANNA R.M., SZUMOWSKI J. MR imaging of prostate cancer with endorectal surface coil technique : correlation with whole mount specimens. Radiology, 1994, 190 : 323-327.
109. RANA A., CHISHOLM M., KHAN M., RASHWAN H.M., ELTON R. A : Conservative managment with symptomatic treatment and delayed hormonal manipulation is justified in men with locally advanced carcinoma of the prostate. Br. J. Urol , 1994, 74, 637-641.
110. RAVERY V., BOCCON-GIBOD L.A., DAUGE-GEFFROY M.C., BILLEBAUD T., BILLEBAUD T., DELMAS V., MEULEMANS A., TOUBLANC M., BOCCON-GIBOD L. : Systematic biopsies accurately predict extracapsular extension od prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology, 1994, 44: 371-376.
111. RENFER L., THOMPSON I.M. : The natural history of the adenocarcinma of the prostate : considerations for management. Cur. Op. Urol., 1994, 4 : 247-250.
112. RUSSELL K.J., CAPLAN R.J., LARAMORE G.E., BURNISON C.M., MAOR M.H., TAYLOR M.E., ZINK D., DAVIS L W., GRIFFIN T.W. Photon vs fast neutron external beam radiotherapy in the teratment of locally advanced prostate cancer : results of a randomized prospective trial. Int. J.Radiat. oncol. Biol. Phys., 1994, 28 : 47-54.
113. RUSSELL K.J., LARAMORE G.E., KRALL J.M., THOMAS F J., MAOR M.H., HENDRICKSON F.R., KRIEGER J.N., GRIFFIN T.W Eight years experience with neutron radiotherapy in the treatment of stage C and D prostate cancer : updated results of the RTOG 77-04 randomized clinical trial. Prostate, 1987, 11 : 183-193.
114. SAGERMAN R.H., CHUN H.C., KING, G.A., CHUNG C.T., DALAL P.S. External beam radiotherapy for carcinoma of the prostate. Cancer, 1987, 63 : 2468-2474.
115. SANDLER H.M., Mc LAUGHLIN P.W., KISH K.E. : Results of 3D conformal radiotherapy in yhe treatment of 707 patients with localized prostate cancer. Int. J.Radiat oncol. Biol. Phys., 1995, 32 (suppl.), abst.1.
116. SANDS M.E., ZAGARS G.K., POLLACK A., VON ESCHENBACH A.C : Serum prostae specific antigen, clinical stage, pathologic grade, and the incidence of nodal metastases in prostate cancer. Urology, 1994, 44 : 215-220.
117. SCARDINO P.T. The pronostic significance of biopsy after radiotherapy for prostate cancer. Sem. Urol., 1983, 1 : 243-252.
118. SCHELLHAMMER P.F., EL-MAHDI A.M., HIGGINS E.M., SCHULTHEISS T.E., LADAGA L.E., BABB T.J.: Prostate biopsy after definitive treatment by interstitial 125 Iodine implant or external beam radiation therapy. J. Urol., 1987, 137 : 897-901.
119. SCHMIDT J.D. Trends in patterns of care for prostatic cancer, 1974-1983 : Results of surveys by the american college of surgeons J. Urol., 1986, 136 : 416-421.
120. SCHNALL M.D., IMAI Y., TOMASZEEOSKI J., POLLACK H M., LENKINSKI R.E., KRESSEL H.Y.: Prostate cancer : local staging with endorectal surface coil MR imaging. Radiology, 1991, 178 : 797-802.
121. SCHRODER F.H., HERMANEK P., DENIS L., FAIR W.R., GOSPODAROWICZ M.K., PAVONE-MACALMUSO M. The TNM classification of prostate cancer. Prostate, 1992, 4 (Suppl): 129-138.
122. SCHRÖDER F.H., VAN DEN OUDEN D., DAVIDSON P., HOP W. Radical prostatectomy in T3 carcinoma of the prostate. A prospective study of 100 consecutive cases. J. Urol., 1993, 149 (suppl) : abst. 543.
123. SCOTT W.W., BOYD H.L. Combined hormone control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate : a retrospective study based upon 25 years of experience. J. Urol., 1969, 101 : 86-92.
124. .SHEARER R.I., DAVIES J.H., GELISTER J.S.K., DEARNALEY D.P. Hormonal cytoreduction and radiotherapy for carcinoma of the prostate. BR. J. Urol., 1992, 69 : 521-524.
125. SHIPLEY W.U., VERHEY L.J., MUNZENRIDER J.E., SUIT H.F., URIE M.M , MC MANUS P.L., YOUNG R.H., SHIPLEY J.W., ZIETMAN A.L., BIGGS P.J. Advanced prostate cancer : the results of a randomized comparative trial of high dose irradiation boosting with conformal Protons compared with conventional dose irradiation using Proton alone. Int. J.Radiat. oncol. Biol. Phys., 1995, 32 : 3-12.
126. SMITH P.H.., SUCIU S , ROBINSON M.R.G., RICHARDS B., BASTABLE J.R.G., GLASHAN R.W., BOUFFIOUX C., LARDENNOIS B., WILLIAMS R.E, DE PAUW M., SYLVESTER R. : A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer : final analysis of a phase III trial of the european organization for research on treatment of cancer. J. Urol., 1986, 136, 619-623.
127. STAME, T.A., FERRARI M.K., SCHMID H.P. The value of serial prostate-specific antigen determinations 5 years after radiotherapy : steeply increasing values characterize 80% of patients J. Urol., 1993, 150 : 1856-1859.
128. STEIN A., DE KERNION J.B., DORE, F., SMITH R.B. Adjuvant radiotherapy in patients post-radical prostatectomy with tumor extending through capsule or positive seminal vesicles. Urology, 1992, 24 : 59-62.
129. STEINECK G., ADOLFSSON J., WHITMORE W.F. Jr : "Local recurrence and disease free survival". Doubtful parameters when comparing non randomized studies of prostate cancer. Scand. J. Urol Nephrol., 1991, 138 (suppl.) : 121.
130. TEMPANY C.M., ZHOU X., ZERHOUNI E.A., RIFKIN M.D., QUINT L.E., PICCOLI C.W., ELLIS J.H., Mc NEIL B.J. Staging of prostate cancer : results of radiology diagnostic oncology group project comparison of three imaging techniques. Radiology, 1994, 192: 47-54
131. TERRIS M.K., Mc NEAL J.E., FREIHA F.S., STAMEY T.A : Efficacy of transrectal ultrasound guided seminal vesicle biopsies in the detection of seminal vesicle invasion by prostate cancer. J. Urol., 1993, 149: 1035-1039.
132. THOMPSON I.M., GERALD W., CHODAK M.D: The natural history of the adenocarcinoma of the prostate. J Cell. Bioch., 1992, 16 (suppl.) : 20-25.
133. TOMLINSON, R.L., CURRIE, D.P., BOYCE W.H. Radical prostatectomy: palliation for stage C carcinoma of the prostate. J. Urol , 1977, 117 : 85-87.
134. VALLANCIEN G., BOCHEREAU G., WETZEL O., BRETHEAU D., PRAPOTNICH D., BOUGARAN J. : Influence of preoperative positive seminal vesicle biopsy on the staging of prostatic cancer. J. Urol., 1994, 152: 1152-1156.
135. VAN DEN OUDEN D., DAVIDSON P.J.T., HOP W., SCHRÖDER F.H. . Radical prostatectomy as monotherapy for locally advanced (stage T3) prostate cancer. J. Urol , 1994, 151 : 646-651.
136. VAN POPPEL H., DE REDDER D., ELGAMAL A.A., VAN DE VOORDE W., WERBROUCK P., ACKAERT K., OYEN R., PITTOMVILS G. BAERT L., and members of the Belgian uro-oncological study group. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer : interim results of a prospective randomized trial. J. Urol , 1995, 154 : 429-434.
137. WATSON. R.B., SOLONAY M.S. : Neoadjuvant hormonal treatment before radical prostatectomy - Sem. Urol. Oncol., 1996, 4 : 48-56.
138. WILLETT C.G., ZIETMAN A.L., SHIPLEY W.U , COEN J.J. : The effect of pelvic radiation therapy on serum levels of prostate specific antigen. J. Urol., 1994, 151 : 1579-1581.
139. WIRTH B., LOCH T., BRÜSKE T., KOVACS G., KIMMING B., BERTERMANN H., STÖCKLE M. Transrectal ultrasound (TRUS) guided combined high dose rate (HDR) brachytherapy of localized prostate cancer : 10 years of experience with a minimum follow up of 5 years. J Urol., 1997, 157 (suppl.) : (P) 289 A.
140. YAMADA A.H., LIESKOVSK, G., CHEN S.C., SKINNER D.G. Rationale for radical prostatectomy and adjuvant therapy in patients with locally advanced prostate cancer. J. Urol , 1993, 149, suppl. : (abst 545).
141. ZAGARS G.K., JOHNSON D.E., VON ESCHENBACH A.C., HUSSEY, D.H. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate : long term results of a prospective randomized study. Int . J. Radiat Oncol. Biol. Phys., 1988, 14 : 1085-1091.
142. ZAGARS G.K., POLLACK A., KAVADI V.S., VON ESCHENBACH A.C. Prostate-specific antigen and radiation therapy for clinical localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1995, 32 : 263-306.
143. ZAGARS G.K., VON ESCHENBACH A.C. The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy. Cancer, 68 : 2370-2377, 1991
144. ZAGARS G K., VON ESCHENBACH A.C., JOHNSON D.E., OSWALD M.J Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation. Cancer, 1987, 60: 1489-1499.
145. ZIETMAN A.L., COEN J.J., DALLO, K.C., SHIPLEY W.U.The treatment of prostate cancer by conventional radiation therapy . an analysis of long-term outcome. Int J Radiat. Oncol. Biol. Phys., 1995, 32 : 287-292.
146. ZIETMAN A.L., COEN J.J., SHIPLEY W.U., WILLETT C G., EFIRD J.T. Radical radiation therapy in the management of prostatic adenocarcinoma : the initial prostate specific antigen value as a predictor of treatment outcome. J. Urol., 1994, 151 : 640-645.
147. ZIETMAN A.L., SHIPLEY W.U. Randomized trials in loco-regionnally confined prostate cancer : past present and future. Seminars in Radiation Oncology, 1993, 3 : 210-220.
148. ZINCKE H., UTZ D.C., TAYLOR W.F. Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostatic cancer : role of adjuvant treatment for residual cancer and in disease progression. J. Urol., 1986, 135 : 1199-1205.